L-asparaginase-induced hypocomplementemia in acute lymphocytic leukemia (ALL) of childhood. 1979

R Shapiro, and Y Kim, and A F Michael, and J M Gerrard, and M Nesbit, and P Coccia, and N K Ramsay, and W Krivit

Serum complement studies were carried out in five children with acute lymphocytic leukemia. During therapy with L-asparaginase, prednisone and vincristine, hypocomplementemia developed in all patients, and disappeared within 2 weeks after the discontinuation of L-asparaginase. Complement breakdown products were not present in plasma. The changes of serum complement levels paralleled those of plasma fibrinogen. These findings suggest that the hypocomplementemia observed in these patients may be related to impaired protein synthesis induced by L-asparaginase.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D003181 Complement C4 A glycoprotein that is important in the activation of CLASSICAL COMPLEMENT PATHWAY. C4 is cleaved by the activated COMPLEMENT C1S into COMPLEMENT C4A and COMPLEMENT C4B. C4 Complement,C4 Complement Component,Complement 4,Complement C4, Precursor,Complement Component 4,Pro-C4,Pro-complement 4,C4, Complement,Complement Component, C4,Complement, C4,Component 4, Complement,Component, C4 Complement,Pro C4,Pro complement 4
D003182 Complement C5 C5 plays a central role in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C5 is cleaved by C5 CONVERTASE into COMPLEMENT C5A and COMPLEMENT C5B. The smaller fragment C5a is an ANAPHYLATOXIN and mediator of inflammatory process. The major fragment C5b binds to the membrane initiating the spontaneous assembly of the late complement components, C5-C9, into the MEMBRANE ATTACK COMPLEX. C5 Complement,Complement 5,Complement C5, Precursor,Complement Component 5,Precursor C5,Pro-C5,Pro-complement 5,C5, Complement,C5, Precursor,C5, Precursor Complement,Complement, C5,Component 5, Complement,Precursor Complement C5,Pro C5,Pro complement 5
D005260 Female Females

Related Publications

R Shapiro, and Y Kim, and A F Michael, and J M Gerrard, and M Nesbit, and P Coccia, and N K Ramsay, and W Krivit
January 1978, Medical and pediatric oncology,
R Shapiro, and Y Kim, and A F Michael, and J M Gerrard, and M Nesbit, and P Coccia, and N K Ramsay, and W Krivit
November 1981, European journal of pediatrics,
R Shapiro, and Y Kim, and A F Michael, and J M Gerrard, and M Nesbit, and P Coccia, and N K Ramsay, and W Krivit
January 1998, Pediatric hematology and oncology,
R Shapiro, and Y Kim, and A F Michael, and J M Gerrard, and M Nesbit, and P Coccia, and N K Ramsay, and W Krivit
May 1971, American journal of diseases of children (1960),
R Shapiro, and Y Kim, and A F Michael, and J M Gerrard, and M Nesbit, and P Coccia, and N K Ramsay, and W Krivit
November 1973, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
R Shapiro, and Y Kim, and A F Michael, and J M Gerrard, and M Nesbit, and P Coccia, and N K Ramsay, and W Krivit
January 2015, Future oncology (London, England),
R Shapiro, and Y Kim, and A F Michael, and J M Gerrard, and M Nesbit, and P Coccia, and N K Ramsay, and W Krivit
September 2002, Blood,
R Shapiro, and Y Kim, and A F Michael, and J M Gerrard, and M Nesbit, and P Coccia, and N K Ramsay, and W Krivit
January 1977, Medical and pediatric oncology,
R Shapiro, and Y Kim, and A F Michael, and J M Gerrard, and M Nesbit, and P Coccia, and N K Ramsay, and W Krivit
January 1990, Haematologica,
R Shapiro, and Y Kim, and A F Michael, and J M Gerrard, and M Nesbit, and P Coccia, and N K Ramsay, and W Krivit
September 1973, Cancer research,
Copied contents to your clipboard!